Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease

Author:

Delbaldo Catherine1,Michiels Stefan2,Rolland Estelle3,Syz Nathalie4,Soria Jean-Charles5,Le Chevalier Thierry1,Pignon Jean Pierre6

Affiliation:

1. Institut Gustave-Roussy; Département de médecine; 39, rue Camille Desmoulins Villejuif Cedex France 94805

2. Institut Gustave-Roussy; Service de biostatistique et d'epidemiologie; 39, rue Camille Desmoulins Villejuif Cedex France 94805

3. Institut Gustave-Roussy; Department of Biostatistics and Epidemiology; 94805 Villejuif Cedex France

4. Institut Gustave-Roussy; Service de biostatistique et d'epidémiologie; 39, rue Camille Desmoulins Villejuif Cedex France 94805

5. Institut Gustave-Roussy; Department of Medecine; 94805 Villejuif Cedex France

6. Institut Gustave Roussy; Biostatistics and Epidemiology Department; 39, rue Camille Desmoulins Villejuif Cedex France 94805

Publisher

Wiley

Subject

Pharmacology (medical)

Reference172 articles.

1. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase II randomized trial;Alberola;J Clin Oncol,2003

2. A randomized study of cisplatin (CDDP), etoposide (VP16) with or without mitomycin (Mito C) in advanced non-small cell lung cancer;Areco;Proc Am Soc Clin Oncol,1989

3. Randomized study of cisplatin and doxorubicin with or without vincristine in non-small cell lung cancer [in Japanese];Bando;Gan To Kagaku Ryoho,1986

4. Gemcitabine (GEM) and cisplatin (PL) versus gemcitabine alone in stage IV non small cell lung cancer (NSCLC): preliminary results of a randomized multicenter phase III study;Berardi;Proc Am Soc Clin Oncol,2001

5. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group;Bonomi;J Clin Oncol,1989

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3